FendX Technologies’ Dr Carolyn Myers Provides REPELWRAP Film Manufacturing Dunmore Partnership Update

In a recent interview with Tracy Weslosky, Dr. Carolyn Myers, President, CEO, and Director of FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF), shared insights into the progress and strategic initiatives surrounding their groundbreaking REPELWRAP™ film, a film that significantly reduces adhesion of bacteria and viruses on surfaces. Collaborating with Dunmore International Corp., their manufacturing partner, FendX has achieved pivotal advancements in automating and refining the production process of REPELWRAP™ film, targeting efficiency enhancements such as reduced changeovers and optimized heating and drying phases. These improvements are key to streamlining production and ensuring the product is cost-effective without sacrificing performance.

Dr. Myers emphasized the critical next steps involving rigorous real-world testing to confirm the film’s durability and efficacy against bacteria and viruses in varied environments, including healthcare and other high traffic venues. Such testing, previously conducted in McMaster University’s lab, demonstrated the film’s promising potential. FendX aims to transition to commercial production by the year’s end, with aspirations to begin revenue generation in the first half of 2025.

The partnership with McMaster University, which facilitated the exclusive licensing of the nanotechnology IP for REPELWRAP™ film, was highlighted as instrumental in meeting developmental milestones. The strategic relationship with Dunmore was also underscored as vital for advancing the product towards commercialization. Dr. Myers exemplifies a commitment to delivering innovative solutions designed to mitigate pathogen transmission on surfaces, marking a significant leap towards enhancing public health safety.

To access the complete interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., click here

Disclaimer: FendX Technologies Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the “Company”), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on www.sedarplus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].